Approaching the sensitized lung patient: risk assessment for donor acceptance

Journal of Thoracic Disease

article

Massimo Mangiola¹  Marilyn Marrari²  Qingyong Xu²  Pablo G. Sanchez³  Adriana Zeevi² 

[1] NYU Langone Transplant Institute;Department of Pathology, University of Pittsburgh Medical Center;Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center

关键词: HLA antibodies;    donor-specific antibodies (DSA);    allosensitization;    lung transplant;    risk stratification;    C1q;    titer;   

DOI  :  10.21037/jtd-2021-21

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

The presence of HLA antibodies is widely recognized as a barrier to solid organ transplantation, and for lung transplant candidates, it has a significant negative impact on both waiting time and waiting list mortality. Although HLA antibodies have been associated with a broad spectrum of allograft damage, precise characterization of these antibodies in allosensitized candidates may enhance their accessibility to transplant. The introduction of Luminex-based single antigen bead (SAB) assays has significantly improved antibody detection sensitivity and specificity, but SAB alone is not sufficient for risk-stratification. Functional characterization of donor-specific antibodies (DSA) is paramount to increase donor accessibility for allosensitized lung candidates. We describe here our approach to evaluate sensitized lung transplant candidates. By employing state-of-the-art technologies to assess histocompatibility and determine physiological properties of circulating HLA antibodies, we can provide our Clinical Team a better risk assessment for lung transplant candidates and facilitate a “road map” to transplant. The cases presented in this paper illustrate the “individualized steps” taken to determine calculated panel reactive antibodies (cPRA), titer and complement-fixing properties of each HLA antibody present in circulation. When a donor is considered, we can better predict the risk associated with potentially crossing HLA antibodies, thereby allowing the Clinical Team to approach allosensitized lung patients with an individualized medicine approach. To facilitate safe access of sensitized lung transplant candidates to potential donors, a synergy between the histocompatibility laboratory and the Clinical Team is essential. Ultimately, donor acceptance is a decision based on several parameters, leading to a risk-stratification unique for each patient.

【 授权许可】

Unknown